04 June 2020
: Case report
Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection
Unusual or unexpected effect of treatment, Clinical situation which can not be reproduced for ethical reasons
Joshua P. Havens12ABDEF*, Nichole N. Regan1BE, Sara H. Bares1ADEFDOI: 10.12659/AJCR.923326
Am J Case Rep 2020; 21:e923326
Abstract
BACKGROUND: Short-course hepatitis C (HCV) treatment with direct-acting antivirals (DAA) under 8 weeks in duration has resulted in variable efficacy rates in HCV mono-infection. Further, DAA courses under 8 weeks in duration have not been studied in HIV/HCV co-infection. We present a case report of 12-week sustained virologic suppression after treatment interruption of ledipasvir/sofosbuvir at 4 weeks in a patient with HIV/HCV co-infection.
CASE REPORT: A 28-year-old male patient diagnosed with well-controlled HIV infection and HCV co-infection (treatment-naïve, genotype 1a, unknown hepatic fibrosis) started a 12-week course of ledipasvir/sofosbuvir (LDV/SOF) for HCV treatment. The patient completed only 4 weeks of LDV/SOF before returning for follow-up 7 weeks after initiation. Ledipasvir/sofosbuvir treatment was discontinued. Sustained virologic suppression at 12 weeks was observed after completion of a short, 4-week course of LDV/SOF.
CONCLUSIONS: Compared to currently recommended treatment durations, clinical trials of short-course DAA treatments of less than 8 weeks have not demonstrated successful rates of SVR12. However, in cases of DAA interruption or incomplete treatment, clinicians may choose to assess for SVR12 prior to continuing or restarting the full treatment course.
Keywords: Antiviral Agents, Hepatitis C, HIV Infections, Adult, Benzimidazoles, coinfection, Drug Therapy, Combination, Fluorenes, Hepatitis C, Chronic, Sofosbuvir, Sustained Virologic Response
SARS-CoV-2/COVID-19
29 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936896
16 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936498
13 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936889
13 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936128
In Press
30 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936967
30 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936896
29 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936313
29 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.935242
Most Viewed Current Articles
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
09 Feb 2022 : Case report
DOI :10.12659/AJCR.934744
Am J Case Rep 2022; 23:e934744